Drug Profile
Research programme: pain therapeutics - AstraZeneca/Xenome
Alternative Names: Venom peptide therapeutics - Xenome/AstraZenecaLatest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune; Xenome
- Developer AstraZeneca; Xenome
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain